Dear Colleagues,

Brain tumors are a heterogeneous group including, among others, gliomas, neuronal tumors, embryonal tumors, meningiomas, other mesenchymal tumors, lymphomas, and sellar tumors. An increasing body of evidence points towards the biological heterogeneity of brain tumors, both at the cellular and molecular level. Accordingly, the upcoming 2021 WHO classification will expand an integrated histological-molecular approach, in which molecular data have a key role in establishing the correct diagnosis. From a therapeutic viewpoint, in some histologies, like lower-grade gliomas and medulloblastomas, such refined diagnosis has led to effective treatments. However, in other tumors, e.g., GBM, notwithstanding the huge advances in cellular and molecular profiling, novel therapeutics have failed to improve prognosis, which remains dismal. These issues foster an increased effort towards a personalized approach to brain tumors, in which a tailored treatment is administered based on the clinical, radiological, histopathological, biological, and molecular features of the single tumor.

Prof. Roberto Pallini
Dr. Quintino Giorgio D’Alessandris

Guest Editors
Message from the Editor-in-Chief

Journal of Personalized Medicine (JPM; ISSN 2075-4426) is an international, open access journal aimed at bringing all aspects of personalized medicine to one platform. JPM publishes cutting edge, innovative preclinical and translational scientific research and technologies related to personalized medicine (e.g., precision medicine, pharmacogenomics/proteomics, systems biology, ‘omics association analysis). JPM is covered in Scopus, the Science Citation Index Expanded (SCIE), PubMed, PMC, Embase, and other databases.

Author Benefits

Open Access:— free for readers, with article processing charges (APC) paid by authors or their institutions.
High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, and other databases.
Journal Rank: JCR - Q2 (Medicine (miscellaneous))